Eli Lilly & Co. (LLY) Tops Q4 EPS by 18c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Eli Lilly (LLY) beats profit forecast amid soaring weight-loss drug demand
February 6, 2024 6:58 AM EST(Updated - February 6, 2024 8:26 AM EST)
Investing.com -- Eli Lilly (NYSE: LLY) has reported fourth-quarter revenue that topped estimates thanks in large part to soaring demand for its weekly diabetes injection.
The U.S. drugmaker's treatment -- branded as Mounjaro -- is in a race with a rival version from Denmark's Novo Nordisk to... More
